GSK To Receive Licence From Spero To Develop, Commercialise Tebipenem Pivoxil HBr

GSK plc (GSK,GSK.L) and Spero Therapeutics, Inc. (SPRO) have entered into a licence agreement for tebipenem pivoxil hydrobromide or tebipenem HBr, a late-stage antibiotic being developed by Spero, as the first oral carbapenem antibiotic to potentially treat complicated urinary tract infections.

GSK will receive an exclusive licence to develop and commercialise tebipenem pivoxil HBr in all countries except Japan and certain other Asian countries. Spero will be responsible for the execution and costs of the remaining phase III clinical trial. GSK will be responsible for the execution and costs of additional clinical development, including regulatory submission and commercialisation activities.

GSK will make an upfront initial payment to Spero of $66 million. Remaining potential payments are milestone-based. GSK has agreed to make a $9 million investment in Spero common stock, not to exceed 19.99% beneficial ownership of Spero by GSK and its affiliates.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Japanese entrepreneur Yusaku Maezawa has selected ten crewmembers, comprising artists, content creators, and athletes, to fly with him on SpaceX's Starship around the Moon on the dearMoon mission. SpaceX's first private lunar flight with dearMoon crew, including two backups, is planned to take place in 2023. Maezawa announced the crew for the mission in a YouTube video and a tweet. SpaceX, owned by Elon Musk, has launched 40 satellites of British communications network OneWeb into orbit. From NASA's Kennedy Space Center or KSC in Florida, Falcon 9 rocket on Thursday evening carried the satellites. The Falcon 9's first stage separated, and it then returned to Earth to make a landing on a SpaceX pad at the nearby Cape Canaveral Space Force Station. Google, owned by Alphabet Inc., plans to merge its teams working on Maps products and the mapping service Waze with effect from December 9, reports said. The decision to consolidate processes comes as the search giant is facing pressure to streamline operations and cut costs. The restructuring is expected to reduce overlapping work across the Waze and Maps products.
Follow RTT